Profile Details

Create Project

★★★★★

☆☆☆☆☆

USD 300 /hr

★★★★★

☆☆☆☆☆

Hire Dr. Lorn K.

United States

USD 300 /hr

Early Drug Discovery Consultant with 10+ Years De-Risking Target ID & Validation

Profile Summary

Helping emerging biotechs and startups move efficiently from target identification to validated lead. I bring 10+ years of cross-functional experience in pharma and agile biotech environments, specializing in oncology (contributing to programs that are currently in Phase II and Phase III), NASH, and asthma. I bridge the gap between cutting-edge technology and practical drug discovery by designing AI-driven disease models and complex phenotypic screening workflows. Contact me to design your next assay strategy, audit CRO data packages, or optimize your early-stage pipeline.

Subject Matter Expertise

• ★ Drug Discovery
• ★ Drug Target Identification
• ★ High Content Screening/Imaging
• ☆ Cell Biology
• ☆ Cell-Based Assays
• ☆ Cell Signaling Pathways
• ☆ Cell Culture
• ☆ Primary Cells
• ☆ Cell Line Engineering
• ☆ High Throughput Screening (HTS)
• ☆ Phenotypic Assays
• ☆ Cancer Research
• ☆ Cancer Biology

Services

• Consulting

Consulting Scientific and Technical Consulting

Work Experience

Cofounder/CSO

PAIVBio Inc

May 2022 - Present

Director

insitro

March 2019 - April 2022

Senior Research Scientist

Ideaya Biosciences

January 2017 - December 2018

Senior Scientific Researcher

Genentech

March 2012 - December 2016

Education

Ph.D., Pharmacology

University of Washington

September 2001 - September 2007

Certifications

• Certification details not provided.

Publications

CONFERENCE PRESENTATION

Lorn Kategaya, Panagiotis Stanitsas, Kara Marie Liu, Kelly Haston, Alicia Lee, Shahin Mohammadi, Haoyang Zheng, Francesco Paolo Casale, Navpreet Ranu, Ahmed Sandakli, Pooja Prasad, et al. (2022). Machine learning methods for detailed characterization of TGFbeta-induced signatures in a large iPSC-derived hepatic stellate cell cohort. EASL International Liver Conference.

JOURNAL ARTICLE

Liang J, Zbieg JR, Blake RA, Chang JH, Daly S, DiPasquale AG, Friedman LS, Gelzleichter T, Gill M, Giltnane JM, et al. (2021). GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer . Journal of medicinal chemistry.

Guan J, Zhou W, Hafner M, Blake RA, Chalouni C, Chen IP, De Bruyn T, Giltnane JM, Hartman SJ, Heidersbach A, et al. (2019). Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility . Cell.

Kategaya L, Perumal SK, Hager JH, Belmont LD (2019). Werner Syndrome Helicase Is Required for the Survival of Cancer Cells with Microsatellite Instability . iScience.

Di Lello P, Pastor R, Murray JM, Blake RA, Cohen F, Crawford TD, Drobnick J, Drummond J, Kategaya L, Kleinheinz T, et al. (2017). Discovery of Small-Molecule Inhibitors of Ubiquitin Specific Protease 7 (USP7) Using Integrated NMR and in Silico Techniques . Journal of medicinal chemistry.

Kategaya L, Di Lello P, Rougé L, Pastor R, Clark KR, Drummond J, Kleinheinz T, Lin E, Upton JP, Prakash S, et al. (2017). USP7 small-molecule inhibitors interfere with ubiquitin binding . Nature.

Joseph JD, Darimont B, Zhou W, Arrazate A, Young A, Ingalla E, Walter K, Blake RA, Nonomiya J, Guan Z, et al. (2016). The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer . eLife.

Wertz IE, Newton K, Seshasayee D, Kusam S, Lam C, Zhang J, Popovych N, Helgason E, Schoeffler A, Jeet S, et al. (2015). Phosphorylation and linear ubiquitin direct A20 inhibition of inflammation . Nature.

Leverson JD, Zhang H, Chen J, Tahir SK, Phillips DC, Xue J, Nimmer P, Jin S, Smith M, Xiao Y, et al. (2015). Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax) . Cell death & disease.